Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Thyroid hemodynamic alterations in Egyptian patients with sickle cell disease: relation to disease severity, total body iron and thyroid function.

ElAlfy MS, El-Sherif NH, Sakr HM, El Ashkar MNM.

Expert Rev Hematol. 2019 Jun 17:1-8. doi: 10.1080/17474086.2019.1629900. [Epub ahead of print]

PMID:
31206301
2.

Angiotensinogen M235T Gene Polymorphism is a Genetic Determinant of Cerebrovascular and Cardiopulmonary Morbidity in Adolescents with Sickle Cell Disease.

ElAlfy MS, Ebeid FSE, Kamal TM, Eissa DS, Ismail EAR, Mohamed SH.

J Stroke Cerebrovasc Dis. 2019 Feb;28(2):441-449. doi: 10.1016/j.jstrokecerebrovasdis.2018.10.019. Epub 2018 Nov 5.

PMID:
30409744
3.

Auditory brainstem response in full-term neonates born to mothers with iron deficiency anemia: relation to disease severity.

ElAlfy MS, El-Farrash RA, Taha HM, Ismail EA, Mokhtar NA.

J Matern Fetal Neonatal Med. 2018 Nov 4:1-8. doi: 10.1080/14767058.2018.1533940. [Epub ahead of print]

PMID:
30293463
4.

Update on corneal neurotisation.

Malhotra R, Elalfy MS, Kannan R, Nduka C, Hamada S.

Br J Ophthalmol. 2019 Jan;103(1):26-35. doi: 10.1136/bjophthalmol-2018-312104. Epub 2018 Sep 21.

PMID:
30242061
5.

Immunological role of CD4+CD28null T lymphocytes, natural killer cells, and interferon-gamma in pediatric patients with sickle cell disease: relation to disease severity and response to therapy.

ElAlfy MS, Adly AAM, Ebeid FSE, Eissa DS, Ismail EAR, Mohammed YH, Ahmed ME, Saad AS.

Immunol Res. 2018 Aug;66(4):480-490. doi: 10.1007/s12026-018-9010-y.

PMID:
29926339
6.

Renal iron deposition by magnetic resonance imaging in pediatric β-thalassemia major patients: Relation to renal biomarkers, total body iron and chelation therapy.

ElAlfy MS, Khalil Elsherif NH, Ebeid FSE, Ismail EAR, Ahmed KA, Darwish YW, Ibrahim AS, Elghamry IRF, Shokrey NA, Alajeil DN.

Eur J Radiol. 2018 Jun;103:65-70. doi: 10.1016/j.ejrad.2018.04.007. Epub 2018 Apr 9.

PMID:
29803388
7.

A pilot study on sperm DNA damage in β-thalassemia major: is there a role for antioxidants?

Elsedfy H, De Sanctis V, Ahmed AY, Mohamed NR, Arafa M, Elalfy MS.

Acta Biomed. 2018 Mar 27;89(1):47-54. doi: 10.23750/abm.v89i1.6836.

8.

Left Ventricular Structural and Functional Changes in Children With β-Thalassemia and Sickle Cell Disease: Relationship to Sleep-disordered Breathing.

Elalfy MS, Youssef OI, Deghedy MMR, Abdel Naby MM.

J Pediatr Hematol Oncol. 2018 Apr;40(3):171-177. doi: 10.1097/MPH.0000000000001096.

PMID:
29494380
9.

Negative Impact of Prolonged Antibiotics or Persistent Diarrhea on Vitamin K1 Levels in 2-24 Weeks aged Egyptian Infants.

Elalfy MS, Ebeid FSE, Elagouza IA, Ibrahim FA, Hassan NBM, Botros BA.

Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018010. doi: 10.4084/MJHID.2018.010. eCollection 2018.

10.

Survival of corneal nerve/sheath structures in organ-cultured donor corneas.

Dhillon VK, Elalfy MS, Messina M, Al-Aqaba M, Dua HS.

Acta Ophthalmol. 2018 May;96(3):e334-e340. doi: 10.1111/aos.13614. Epub 2017 Nov 29.

11.

Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.

Elalfy MS, Adly A, Awad H, Tarif Salam M, Berdoukas V, Tricta F.

Am J Hematol. 2018 Feb;93(2):262-268. doi: 10.1002/ajh.24966. Epub 2017 Nov 27.

12.

Neurocognitive dysfunction in children with β thalassemia major: psychometric, neurophysiologic and radiologic evaluation.

Elalfy MS, Aly RH, Azzam H, Aboelftouh K, Shatla RH, Tarif M, Abdatty M, Elsayed RM.

Hematology. 2017 Dec;22(10):617-622. doi: 10.1080/10245332.2017.1338212. Epub 2017 Jun 16.

PMID:
28621205
13.

Dynamics of big bubble formation in deep anterior lamellar keratoplasty by the big bubble technique: in vitro studies.

Dua HS, Faraj LA, Kenawy MB, AlTaan S, Elalfy MS, Katamish T, Said DG.

Acta Ophthalmol. 2018 Feb;96(1):69-76. doi: 10.1111/aos.13460. Epub 2017 May 8.

14.

Klf10 Gene, a Secondary Modifier and a Pharmacogenomic Biomarker of Hydroxyurea Treatment Among Patients With Hemoglobinopathies.

Elalfy MS, El Sherif NH, Kamal TM, Aly NH.

J Pediatr Hematol Oncol. 2017 Apr;39(3):e155-e162. doi: 10.1097/MPH.0000000000000762.

PMID:
28085748
15.

Amnion-assisted conjunctival epithelial redirection in limbal stem cell grafting.

Dua HS, Miri A, Elalfy MS, Lencova A, Said DG.

Br J Ophthalmol. 2017 Jul;101(7):913-919. doi: 10.1136/bjophthalmol-2015-307935. Epub 2016 Nov 25.

PMID:
27888184
16.

Optical coherence tomography characteristics of different types of big bubbles seen in deep anterior lamellar keratoplasty by the big bubble technique.

AlTaan SL, Termote K, Elalfy MS, Hogan E, Werkmeister R, Schmetterer L, Holland S, Dua HS.

Eye (Lond). 2016 Nov;30(11):1509-1516. doi: 10.1038/eye.2016.129. Epub 2016 Jul 29.

17.

Viruses, anti-viral therapy, and viral vaccines in children with immune thrombocytopenia.

Elalfy MS, Nugent D.

Semin Hematol. 2016 Apr;53 Suppl 1:S70-2. doi: 10.1053/j.seminhematol.2016.04.021. Epub 2016 Apr 7. Review.

PMID:
27312173
18.

Determination of Human Hemoglobin Derivatives.

Attia AM, Ibrahim FA, Abd El-Latif NA, Aziz SW, Abdelmottaleb Moussa SA, Elalfy MS.

Hemoglobin. 2015;39(5):371-4. doi: 10.3109/03630269.2015.1062775. Epub 2015 Jul 21.

PMID:
26193973
19.

Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.

Elalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, Elalfy OM.

Eur J Haematol. 2016 Mar;96(3):318-26. doi: 10.1111/ejh.12594. Epub 2015 Jun 25.

PMID:
26018112
20.

Corneal hypoesthesia with normal sub-basal nerve density following surgery for trigeminal neuralgia.

Dhillon VK, Elalfy MS, Al-Aqaba M, Gupta A, Basu S, Dua HS.

Acta Ophthalmol. 2016 Feb;94(1):e6-10. doi: 10.1111/aos.12697. Epub 2015 Apr 3.

21.

Big bubble deep anterior lamellar keratoplasty: the collagen layer in the wall of the big bubble is unique.

Dua HS, Mastropasqua L, Faraj L, Nubile M, Elalfy MS, Lanzini M, Calienno R, Said DG.

Acta Ophthalmol. 2015 Aug;93(5):427-30. doi: 10.1111/aos.12714. Epub 2015 Mar 30.

22.

Endothelial cell loss following tissue harvesting by pneumodissection for endothelial keratoplasty: an ex vivo study.

Altaan SL, Gupta A, Sidney LE, Elalfy MS, Agarwal A, Dua HS.

Br J Ophthalmol. 2015 May;99(5):710-3. doi: 10.1136/bjophthalmol-2014-306560. Epub 2015 Mar 4.

PMID:
25740808
23.

Oxidant/antioxidant status in children and adolescents with immune thrombocytopenia (ITP) and the role of an adjuvant antioxidant therapy.

Elalfy MS, Elhenawy YI, Deifalla S, Hegazy M, Sabra A, Abdelaziz Y.

Pediatr Blood Cancer. 2015 May;62(5):830-7. doi: 10.1002/pbc.25434. Epub 2015 Feb 7. Erratum in: Pediatr Blood Cancer. 2015 Aug;62(8):1494. Elalfy, Mohssen S [corrected to Elalfy, Mohsen Saleh].

PMID:
25663642
24.

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.

Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.

Eur J Haematol. 2015 Nov;95(5):411-20. doi: 10.1111/ejh.12507. Epub 2015 Mar 27.

PMID:
25600572
25.

Deep anterior lamellar keratoplasty--triple procedure: a useful clinical application of the pre-Descemet's layer (Dua's layer).

Zaki AA, Elalfy MS, Said DG, Dua HS.

Eye (Lond). 2015 Mar;29(3):323-6. doi: 10.1038/eye.2014.273. Epub 2014 Oct 31.

26.

Masquerade ectasia.

Dhillon VK, Elalfy MS, Albert R, Shah PA, Mahmood K, Dua HS.

Br J Ophthalmol. 2014 Nov;98(11):1601-2. doi: 10.1136/bjophthalmol-2014-305251. Epub 2014 Sep 2. No abstract available.

PMID:
25185251
27.

Fine needle diathermy occlusion of corneal vessels.

Faraj LA, Elalfy MS, Said DG, Dua HS.

Br J Ophthalmol. 2014 Sep;98(9):1287-90. doi: 10.1136/bjophthalmol-2014-304891. Epub 2014 Apr 29.

PMID:
24782468
28.

Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting.

Said DG, Elalfy MS, Gatzioufas Z, El-Zakzouk ES, Hassan MA, Saif MY, Zaki AA, Dua HS, Hafezi F.

Ophthalmology. 2014 Jul;121(7):1377-82. doi: 10.1016/j.ophtha.2014.01.011. Epub 2014 Feb 25.

PMID:
24576886
29.

The collagen matrix of the human trabecular meshwork is an extension of the novel pre-Descemet's layer (Dua's layer).

Dua HS, Faraj LA, Branch MJ, Yeung AM, Elalfy MS, Said DG, Gray T, Lowe J.

Br J Ophthalmol. 2014 May;98(5):691-7. doi: 10.1136/bjophthalmol-2013-304593. Epub 2014 Feb 16.

PMID:
24532799
30.

Intracranial haemorrhage is linked to late onset vitamin K deficiency in infants aged 2-24 weeks.

Elalfy MS, Elagouza IA, Ibrahim FA, AbdElmessieh SK, Gadallah M.

Acta Paediatr. 2014 Jun;103(6):e273-6. doi: 10.1111/apa.12598. Epub 2014 Mar 18.

PMID:
24528309
31.

Anaesthetic corneas with intact sub-basal nerve plexus.

Dhillon VK, Elalfy MS, Al-Aqaba M, Dua HS.

Br J Ophthalmol. 2014 Mar;98(3):417-8. doi: 10.1136/bjophthalmol-2013-303890. Epub 2014 Jan 3. No abstract available.

PMID:
24390169
32.

Atypical hydrops in keratoconus.

Said DG, Faraj L, Elalfy MS, Miri A, Maharajan SV, Dua HS.

Int Ophthalmol. 2014 Aug;34(4):951-5. doi: 10.1007/s10792-013-9881-9. Epub 2013 Nov 19.

PMID:
24249457
33.

Corneal microcysts.

Dhillon VK, Faraj LA, Elalfy MS, Bhatt U, Said DG, Dua HS.

Br J Ophthalmol. 2014 Jan;98(1):138, 147-8. doi: 10.1136/bjophthalmol-2013-303705. Epub 2013 Oct 4. No abstract available.

PMID:
24096522
34.

Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.

Elalfy MS, Adly AA, Ismail EA, Elhenawy YI, Elghamry IR.

Eur J Haematol. 2013 Dec;91(6):522-33. doi: 10.1111/ejh.12182. Epub 2013 Oct 5.

PMID:
23927461
35.

Intra-lesional 5 fluorouracil for the management of recurrent pterygium.

Said DG, Faraj LA, Elalfy MS, Yeung A, Miri A, Fares U, Otri AM, Rahman I, Maharajan S, Dua HS.

Eye (Lond). 2013 Oct;27(10):1123-9. doi: 10.1038/eye.2013.135. Epub 2013 Jun 28.

36.

Sequential selective same-day suture removal in the management of post-keratoplasty astigmatism.

Fares U, Mokashi AA, Elalfy MS, Dua HS.

Eye (Lond). 2013 Sep;27(9):1032-7. doi: 10.1038/eye.2013.126. Epub 2013 Jun 7.

37.

Three decades of experience in managing immune thrombocytopenia in children in Arab countries.

Elalfy MS.

Semin Hematol. 2013 Jan;50 Suppl 1:S22-5. doi: 10.1053/j.seminhematol.2013.03.019. Review.

38.

Effect of antioxidant therapy on hepatic fibrosis and liver iron concentrations in β-thalassemia major patients.

Elalfy MS, Adly AA, Attia AA, Ibrahim FA, Mohammed AS, Sayed AM.

Hemoglobin. 2013;37(3):257-76. doi: 10.3109/03630269.2013.778866. Epub 2013 Apr 9.

PMID:
23565660
39.

Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.

Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA.

Ann Hepatol. 2013 Jan-Feb;12(1):54-61.

40.

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.

Ann Hematol. 2013 Jan;92(2):211-9. doi: 10.1007/s00277-012-1588-x. Epub 2012 Oct 21.

41.

Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children.

Elalfy MS, Elbarbary NS, Eldebeiky MS, El Danasoury AS.

Pediatr Hematol Oncol. 2012 Aug;29(5):485-93. doi: 10.3109/08880018.2012.704624.

PMID:
22866674
42.

D-dimer and portal vein status in splenectomized Egyptian β-thalassemia major patients: a prospective single-thalassemia center experience.

Elalfy MS, Andrawes NG, Sadek AM, Hussein O, Abdou A.

Pediatr Hematol Oncol. 2012 Apr;29(3):247-53. doi: 10.3109/08880018.2011.645186.

PMID:
22475301
43.

Pattern of milk feeding and family size as risk factors for iron deficiency anemia among poor Egyptian infants 6 to 24 months old.

Elalfy MS, Hamdy AM, Maksoud SS, Megeed RI.

Nutr Res. 2012 Feb;32(2):93-9. doi: 10.1016/j.nutres.2011.12.017.

PMID:
22348457
44.

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A.

Haematologica. 2012 Jun;97(6):842-8. doi: 10.3324/haematol.2011.049957. Epub 2012 Jan 22.

45.

A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major.

Elalfy MS, Massoud W, Elsherif NH, Labib JH, Elalfy OM, Elaasar S, von Mackensen S.

Pediatr Blood Cancer. 2012 Jun;58(6):910-5. doi: 10.1002/pbc.23413. Epub 2012 Jan 9.

PMID:
22232075
46.

Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program.

el-Danasoury AS, Eissa DG, Abdo RM, Elalfy MS.

Transfusion. 2012 Jan;52(1):43-7. doi: 10.1111/j.1537-2995.2011.03234.x. Epub 2011 Jul 11.

PMID:
21745214
47.

Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia.

Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, El-Ali A, Roubert B, El-Beshlawy A.

Eur J Haematol. 2011 Oct;87(4):355-65. doi: 10.1111/j.1600-0609.2011.01662.x. Epub 2011 Jul 31.

48.

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.

Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, Roubert B, El-Beshlawy A.

Eur J Haematol. 2011 Oct;87(4):349-54. doi: 10.1111/j.1600-0609.2011.01661.x. Epub 2011 Jul 26.

49.

Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A.

Abdel-Messih IY, Habashy DM, Moftah SG, ElAlfy MS.

Haemophilia. 2011 May;17(3):490-3. doi: 10.1111/j.1365-2516.2010.02447.x. Epub 2011 Mar 4. Erratum in: Haemophilia. 2011 Nov;17(6):979. El-Alfy, M [corrected to ElAlfy, M S].

PMID:
21371185
50.

Romiplostim in children with chronic refractory ITP: randomized placebo controlled study.

Elalfy MS, Abdelmaksoud AA, Eltonbary KY.

Ann Hematol. 2011 Nov;90(11):1341-4. doi: 10.1007/s00277-011-1172-9. Epub 2011 Feb 12.

PMID:
21318572

Supplemental Content

Loading ...
Support Center